Shingles vaccine study aims to protect vulnerable patients on immune drugs
NCT ID NCT07280741
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This study tests the shingles vaccine in 200 adults with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are taking immune-suppressing drugs. The goal is to see if the vaccine triggers a strong immune response and prevents shingles. Participants will receive two doses of the vaccine and be monitored for side effects and antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital das Clínicas
RECRUITINGSão Paulo, São Paulo, 05403-010, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.